Log in to your Inderes Free account to see all free content on this page.
Oncopeptides
5.35 SEK
+1.90 %
Less than 1K followers
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.90 %
-7.60 %
+11.57 %
+272.41 %
+264.75 %
+266.64 %
-54.62 %
-95.28 %
-81.48 %
Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.
Read moreMarket cap
1.46B SEK
Turnover
4.8M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
19.2.
2026
Annual report '25
13.5.
2026
Interim report Q1'26
21.5.
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Oncopeptides, Capital Markets Update, 2025
Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
